News | Radiation Therapy | October 17, 2018

IBA Dosimetry Enters Interoperability Agreement With Varian for Dolphin Monitoring

After successful validation of Dolphin interoperability, online patient dose measurements during actual treatment delivery will enable verification of the correctness of each treatment fraction

IBA Dosimetry Enters Interoperability Agreement With Varian for Dolphin Monitoring

October 17, 2018 — IBA (Ion Beam Applications S.A.) announced it has entered into an agreement with Varian with the goal of validating the Dolphin transmission detector for online monitoring of patient treatment.

With the health, security and safety of patients in focus, modern radiation therapy has become highly specialized, which has led to different complex treatment techniques being developed and used daily in patient cancer therapy. This in turn requires new and comprehensive quality assurance (QA) solutions that address the growing number of possible sources and impact of dose deviations, in particular for high-dose cases.

For online patient plan monitoring, IBA Dosimetry is set to release the Dolphin online solution with its Compass 3D verification software, and has therefore entered into an interoperability agreement with Varian.

The Dolphin online functionality enables the measurement of each fraction dose and the verification of the actual radiation dose delivered to patients. The ability to measure treatment accuracy fraction by fraction will provide the confidence and safety needed to deliver the highest quality of care to the patient.

Dolphin includes the following five checks for verification of the complete treatment chain:

  • Real measurement of the plan delivery. In contrast to solutions that purely recalculate the patient plan via log files, the Dolphin advanced high-resolution ionization chamber detector array enables real measurements of each fraction dose and detection of errors in treatment delivery, such as beam line defects, multileaf collimator (MLC) deviations, dose rate changes, flatness/symmetry drifts, gantry positioning errors, etc.;
  • Verification of the real patient plan where no surrogate QA plan is required;
  • Secondary dose calculation with treatment planning system (TPS)-class algorithm. Secondary verification of the TPS dose calculation enables detection of errors in the TPS algorithm, TPS performance or in the TPS export;
  • Machine constancy checks with myQA. In addition, Dolphin’s detector array is optimized to find deviations and trends in linear accelerator (LINAC) constancy for profiles, output and wedge factors; and
  • Independent verification of the treatment planning system. The independent beam model of Dolphin’s verification software enables detection of errors in the TPS configuration and performance, its beam model, commissioning, or the LINAC calibration
     

Dolphin is currently in clinical use around the world for advanced measurement-based pre-treatment patient QA.

For more information: www.iba-dosimetry.com

Related Content

Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
Elekta Unity MR Linac system
News | Radiation Oncology | January 30, 2020
January 30, 2020 — Elekta announced that it signed a contract wit
ringing the cancer bell can do more harm than good, says an ASTRO study

Image courtesy of ASTRO

News | Radiation Oncology | January 27, 2020
January 27, 2020 — It's a scene that some cancer patients dream about: they celebrate the end of a course of radiatio
Lung cancer patients who are inactive prior to chemoradiation are less likely to tolerate treatment and more likely to see their cancer return
News | Lung Cancer | January 08, 2020
January 8, 2020 — Numerous ...